# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Citigroup analyst Yigal Nochomovitz maintains Ovid Therapeutics (NASDAQ:OVID) with a Neutral and lowers the price target fro...
B. Riley Securities analyst Kalpit Patel initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating and announc...
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating a...
Wedbush analyst Laura Chico initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Outperform rating and announces Pri...
The Dow Jones index closed higher by over 400 points on Wednesday. When insiders purchase or sell shares, it indicates their co...
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.220) per share which missed the analyst consensus estimate of ...